Hans Lee
Dr. Hans Lee is an Associate Professor and Director of Multiple Myeloma Clinical Research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center. He received his MD from Indiana University. Subsequently, he completed his internal medicine residency training at Washington University in St. Louis, followed by a hematology/oncology fellowship at MD Anderson Cancer Center. Dr. Lee's clinical and research efforts are focused on advancing the care and treatment of patients with multiple myeloma. Specifically, his primary research goals are directed towards developing novel approaches to treat multiple myeloma through early phase investigator-initiated and industry-sponsored clinical trials with a strong translational emphasis to interrogate myeloma pathobiology and mechanisms of drug response and resistance. Dr. Lee’s research has been funded by the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and has published in a number of peer-reviewed journals including the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Blood.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:TakedaDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:RegeneronDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AlexionDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MenariniDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PfizerDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Bristol Myers SquibbDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AllogeneDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GlaxoSmithKlineDate added:01/12/2025Date updated:01/12/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SanofiDate added:01/12/2025Date updated:01/12/2025